BYDUREON Safety and Tolerability Pooled Summary Data Presented at ADA 2010
ORLANDO, Fla.—-Amylin Pharmaceuticals, Inc. , Eli Lilly and Company and Alkermes, Inc. today announced results of an analysis of pooled safety data from three completed randomized controlled trials that showed the investigational product BYDUREON™ , dosed once weekly, was generally well-tolerated with a low discontinuation rate due to serious adverse events similar to pooled comparators in …
Reverse Phone Detective Review And Testimonial